Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate…

By M. Topp, P. Kufer, N. Gökbuget, M. Goebeler, M. Klinger, S. Neumann, H. Horst, T. Raff, A. Viardot, M. Schmid and 19 more. Journal of Clinical Oncology, 2011

906 citations recorded by the source corpus.

Subfields: Oncology, Public Health, Environmental and Occupational Health, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/233f2119d36717b7eed01a92db14bb8d4cd1c657

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. C. June
2. S. Grupp
3. D. Porter
4. S. Maude
5. D. Teachey
6. B. Levine
7. J. Kochenderfer
8. T. Fry

In Radiology, Nuclear Medicine and Imaging

1. C. June
2. Dimiter S. Dimitrov

Citations in the corpus

• Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (2015, background): “Central nervous system toxicity has also been associated with other T cell–engaging therapies such as blinatumomab (22, 23), supporting the concept that T cell activation leads to these neurologic events (12).”
• CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. (2015, background): “Neurologic toxicities have been reported after T cell engaging therapies, including distinct CAR-modified T cell therapies as well as blinatumomab.(25,74,75) Global encephalopathy is the most common toxicity, but seizures have also been reported.”
• Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. (2018, result): “Additional studies need to determine the role of HSCT in this setting, particularly regarding indications for HSCT. Treatment of patients with persistent chemotherapy-resistant disease after conventional treatment remains a major challenge in the management of pediatric and adult ALL, with high rela”
• Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. (2013, background): “21 CD19-negative blasts after treatment with the anti-CD3/CD19 bi-specific antibody blinatumomab (37, 38).”
• CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL (2017, positive): “Blinatumomab, a CD19xCD3 bispecific antibody, mediates impressive effects in patients with overt 8,9 and minimal residual disease (MRD) levels of B-ALL 10 .”